Macquarie Group’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-61,255
| Closed | -$325K | – | 1314 |
|
|
2025
Q3 | $325K | Hold |
61,255
| – | – | ﹤0.01% | 1456 |
|
|
2025
Q2 | $210K | Hold |
61,255
| – | – | ﹤0.01% | 1533 |
|
|
2025
Q1 | $181K | Hold |
61,255
| – | – | ﹤0.01% | 1538 |
|
|
2024
Q4 | $187K | Hold |
61,255
| – | – | ﹤0.01% | 1517 |
|
|
2024
Q3 | $156K | Hold |
61,255
| – | – | ﹤0.01% | 1564 |
|
|
2024
Q2 | $200K | Sell |
61,255
-1,529
| -2% | -$6.71K | ﹤0.01% | 1555 |
|
|
2024
Q1 | $325K | Buy |
62,784
+1,529
| +2% | +$8.23K | ﹤0.01% | 1482 |
|
|
2023
Q4 | $265K | Hold |
61,255
| – | – | ﹤0.01% | 1528 |
|
|
2023
Q3 | $161K | Hold |
61,255
| – | – | ﹤0.01% | 1551 |
|
|
2023
Q2 | $216K | Hold |
61,255
| – | – | ﹤0.01% | 1544 |
|
|
2023
Q1 | $189K | Hold |
61,255
| – | – | ﹤0.01% | 1557 |
|
|
2022
Q4 | $259K | Hold |
61,255
| – | – | ﹤0.01% | 1575 |
|
|
2022
Q3 | $145K | Hold |
61,255
| – | – | ﹤0.01% | 1672 |
|
|
2022
Q2 | $175K | Hold |
61,255
| – | – | ﹤0.01% | 1746 |
|
|
2022
Q1 | $176K | Hold |
61,255
| – | – | ﹤0.01% | 1829 |
|
|
2021
Q4 | $186K | Sell |
61,255
-6,993
| -10% | -$30.4K | ﹤0.01% | 1778 |
|
|
2021
Q3 | $478K | Buy |
68,248
+6,354
| +10% | +$47.6K | ﹤0.01% | 1686 |
|
|
2021
Q2 | $568K | Hold |
61,894
| – | – | ﹤0.01% | 1681 |
|
|
2021
Q1 | $601K | Sell |
61,894
-303
| -0.5% | -$3.38K | ﹤0.01% | 1498 |
|
|
2020
Q4 | $638K | Hold |
62,197
| – | – | ﹤0.01% | 1409 |
|
|
2020
Q3 | $628K | Hold |
62,197
| – | – | ﹤0.01% | 1350 |
|
|
2020
Q2 | $649K | Buy |
62,197
+942
| +2% | +$9.75K | ﹤0.01% | 1293 |
|
|
2020
Q1 | $517K | Hold |
61,255
| – | – | ﹤0.01% | 1262 |
|
|
2019
Q4 | $536K | Sell |
61,255
-1,062,622
| -95% | -$8.8M | ﹤0.01% | 1385 |
|
|
2019
Q3 | $12.1M | Buy |
1,123,877
+70,475
| +7% | +$761K | 0.02% | 563 |
|
|
2019
Q2 | $13.4M | Buy |
1,053,402
+66,234
| +7% | +$1.53M | 0.02% | 550 |
|
|
2019
Q1 | $38.3M | Buy |
987,168
+161,972
| +20% | +$4.95M | 0.07% | 316 |
|
|
2018
Q4 | $16.8M | Buy |
825,196
+176,733
| +27% | +$5.3M | 0.03% | 469 |
|
|
2018
Q3 | $29.7M | Buy |
648,463
+175,699
| +37% | +$8.47M | 0.05% | 386 |
|
|
2018
Q2 | $28M | Buy |
+472,764
| New | +$27.4M | 0.05% | 410 |
|
|
2018
Q1 | – | Sell |
-300
| Closed | -$30K | – | 2316 |
|
|
2017
Q4 | $30K | Buy |
+300
| New | +$33.6K | ﹤0.01% | 2171 |
|
|
2015
Q4 | – | Sell |
-400
| Closed | -$30K | – | 1544 |
|
|
2015
Q3 | $30K | Hold |
400
| – | – | ﹤0.01% | 1550 |
|
|
2015
Q2 | $47K | Sell |
400
-8,514
| -96% | -$1.54M | ﹤0.01% | 1568 |
|
|
2015
Q1 | $2.1M | Buy |
8,914
+4,864
| +120% | +$1.04M | ﹤0.01% | 1010 |
|
|
2014
Q4 | $767K | Buy |
+4,050
| New | +$899K | ﹤0.01% | 1206 |
|
Other funds holding PBYI
ACA
OSAM
Macquarie Group's PBYI Position: Q4 2025 in Review
Macquarie Group sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 61,255 shares — an estimated $325K sold.
Macquarie Group first reported a position in PBYI in Q4 2014 and held it in 35 quarters. The position peaked at $38.3M in Q1 2019. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.
- Macquarie Group reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
- Macquarie Group sold 61,255 Puma Biotechnology shares in Q4 2025, an estimated $325K.
- Macquarie Group first reported a position in Puma Biotechnology in Q4 2014 and held it in 35 quarters.
- Macquarie Group's Puma Biotechnology position peaked at $38.3M in Q1 2019.
- 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.
Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.